Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Monte Rosa Therapeutics Inc (GLUE) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $0.00 | $-8.02M | — | — | — |
| 2020 | $0.00 | $-35.88M | — | — | — |
| 2021 | $0.00 | $-73.96M | — | — | — |
| 2022 | $0.00 | $-108.50M | — | — | — |
| 2023 | $0.00 | $-135.35M | — | — | — |
| 2024 | $75.62M | $-72.70M | 89.26% | -107.26% | -96.14% |
| 2025 | $123.67M | $-38.63M | 93.24% | -43.83% | -31.23% |
Frequently asked questions
What is Monte Rosa Therapeutics Inc's revenue?
Monte Rosa Therapeutics Inc's trailing twelve-month revenue is $42.95M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is GLUE?
In its most recent fiscal year, GLUE ran a gross margin of 93.24%, an operating margin of -43.83%, and a net margin of -31.23%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does GLUE generate?
GLUE produced $-27.50M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is GLUE's balance sheet healthy?
GLUE holds $129.88M in cash and equivalents against — in long-term debt, on $233.06M of shareholder equity. That debt is best read against the cash flow the business throws off each year.